This M-DNA technology has already been used successfully against MERS in the Middle East. We do know this technology works.
We already know that MERS and SARS-CoV-2 aren't the same viruses and don't produce the same disease. Knowing the technology of producing a vaccine that can work is not the same thing as knowing that the M-DNA technology results in immunity against SARS-CoV-2.
We will have to shorten the approval process, even if we have to lock up all the damn trial lawyers. The real question is will the vaccine have a net benefit? The MERS experience says almost certainly yes. We can not go futzing around worrying about lawyers for 18 to 24 months once a viable vaccine is identified. Just make it illegal to sue for any ill effects of the vaccine.
I don't think the drug company lawyers will be the main obstacle. Most clinical trails of much more toxic anti-cancer drugs do protect the medical personnel, institutions, and manufacturers from lawsuits concerning adverse events that take place as result of the clinical trial treatment. But, to be fair, they do not involve exposing patients to known disease causing pathogens.
In my opinion, it will be the conservative MDs in charge of the FDA and the individual hospital Institutional Review Boards of all participating medical institutions, who will be the biggest obstacles. They all must approve any trial protocol that shortens the approval process for a new vaccine.
Any vaccine trial will examine a population of healthy people from age 18 (perhaps lower?) to age 55. Usually a separate trial, or separate cohort, tests the vaccine in older people, such as ages 55-70. Statistically meaningful results require separating these age groups. On a practical level, it also takes longer to accrue patients in the older 55-70 age group.
Let's assume, for the sake of argument, that there is a highly motivated group of immunized people in the 18-55 age group who are willing to be challenged by infectious SARS-CoV-2 virus. And let's also assume that all legal obstacles for this live virus challenge are eliminated.
Will the ages of this highly motivated sub-group represent the ages of all people who were immunized? Or will they be skewed to the younger side, for example in the range of 18-35?
Will the results of the live virus challenge apply only to the younger 18-35 age group? Or will it apply to the full 18-55 age group of the trial? If the results only apply to the 18-35 group, how much longer will it take to establish vaccine efficacy for the entire 18-55 age group? I hope you see where I'm going. This scenario that I imagined, would take a lot longer than you think. There may be ways to write a vaccine protocol to deal with this potential obstacle. But it would require careful thought so that it actually results in vaccine trials that actually provide useful results.
Bottom line – challenging immunized patients with live virus may not be the short-cut that you hope it to be. The entire population of immunized patients has to be tested for efficacy, not just a highly motivated sub-group.